“This usual chain of decisions … has been disrupted. And without clarity and coordination, millions may not be able to have ...

As a summer COVID-19 surge hits Michigan, unanswered questions abound about eligibility, insurance coverage and when new vaccines will be available.

James Brumley has positions in Coca-Cola. The Motley Fool has positions in and recommends Amazon, Equifax, MercadoLibre, ...

Pfizer faces challenges from pricing pressures, a 2026 patent cliff, and weak R&D momentum. Click here to find out why I rate PFE stock a Sell.

Treatment for advanced bladder cancer had not significantly changed for 40 years. Now thousands are set to benefit ...

Rare cancers make up one in four cancer diagnoses in the U.S., yet many of them lack a standardized procedure of care for ...

"Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since ...

Financisation is killing the economy. When companies such as Apple and Pfizer spend more on share buy-backs than on R&D, ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

The combination will now join Bristol Myers Squibb’s Opdivo in the list of bladder cancer drugs available on the NHS.

Achieve Life Sciences Inc. (NASDAQ:ACHV) is moving closer to a pivotal moment as it seeks FDA approval for cytisinicline, a ...

Although infection prevention is an essential part of every rheumatologist’s routine, balancing efficacy, risk and individual patient choices — all while contending with a seemingly constant flow of ...